上(shang)(shang)海復星(xing)醫藥(yao)(yao)(yao)(集團)股份有限公司公布2022年(nian)度(du)經(jing)營(ying)業(ye)(ye)績。2022年(nian)，復星(xing)醫藥(yao)(yao)(yao)實(shi)現營(ying)業(ye)(ye)收(shou)入(ru)(ru)439.52億(yi)元(yuan)(yuan)，同比(bi)增(zeng)長12.66%；實(shi)現歸屬(shu)于上(shang)(shang)市公司股東(dong)的扣(kou)除非經(jing)常性損益的凈利潤38.73億(yi)元(yuan)(yuan)，同比(bi)增(zeng)長18.17%。全年(nian)研(yan)發(fa)(fa)投入(ru)(ru)共計58.85億(yi)元(yuan)(yuan)，同比(bi)增(zeng)長18.22%；其(qi)(qi)中，研(yan)發(fa)(fa)費用(yong)為43.02 億(yi)元(yuan)(yuan)，同比(bi)增(zeng)加(jia)4.65 億(yi)元(yuan)(yuan)，增(zeng)長12.12%。制藥(yao)(yao)(yao)業(ye)(ye)務研(yan)發(fa)(fa)投入(ru)(ru)50.97億(yi)元(yuan)(yuan)，同比(bi)增(zeng)長13.62%，制藥(yao)(yao)(yao)業(ye)(ye)務研(yan)發(fa)(fa)投入(ru)(ru)占制藥(yao)(yao)(yao)業(ye)(ye)務收(shou)入(ru)(ru)的16.54%；其(qi)(qi)中，研(yan)發(fa)(fa)費用(yong)為35.52 億(yi)元(yuan)(yuan)，占制藥(yao)(yao)(yao)業(ye)(ye)務收(shou)入(ru)(ru)的11.53%。(醫藥(yao)(yao)(yao)健聞)